Nuwellis Inc. Announces Pilot Agreement With DaVita Inc. To Pilot Aquadex Ultrafiltration Therapy To Treat Adult Patients With Congestive Heart Failure And Related Conditions Within Select U.S. Markets
Portfolio Pulse from Happy Mohamed
Nuwellis, Inc. (NASDAQ:NUWE) has entered into a Supply and Collaboration Agreement with DaVita Inc. (NYSE:DVA) to pilot Aquadex ultrafiltration therapy for adult patients with congestive heart failure and related conditions within select U.S. markets. The pilot program is expected to launch by the end of Q3 2023 and extend through May 31, 2024.
June 20, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DaVita partners with Nuwellis to pilot Aquadex ultrafiltration therapy, potentially expanding its service offerings and reducing healthcare costs for providers and payers.
The partnership with Nuwellis allows DaVita to pilot Aquadex ultrafiltration therapy, which could expand its service offerings and reduce healthcare costs for providers and payers. This could positively impact DVA's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Nuwellis enters into a Supply and Collaboration Agreement with DaVita to pilot Aquadex ultrafiltration therapy, potentially expanding access to millions of heart failure patients in the U.S.
The partnership with DaVita could potentially expand access to ultrafiltration therapy for millions of heart failure patients in the U.S., which could lead to increased adoption of Nuwellis' Aquadex therapy. This could positively impact NUWE's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100